Does the magnitude of OncoType recurrence score above 26 inform decision between TC and AC/T in ER+ HER2- 1-3 node positive, postmenopausal patients with breast cancer?

Is the marginal advantage of AC/T in 1-3 node positive outweighed by toxicity such as risk of cardiotoxicity and leukemia, regardless of RS?

Answer from: Medical Oncologist at Community Practice

We don't have any evidence for correlating recurrence score with choice of chemotherapy. Based on RxPONDER, we know that patients with 1-3 positive lymph nodes and scores less than 25, do not benefit from chemotherapy. Based on retrospective data, we have enough evidence that scores more than 30 wou...

Comments

Medical Oncologist at British Columbia Cancer Agency
I would agree with Dr. @Peddi. In HR+HER2- N1 dis...

Medical Oncologist at Onc San Antonio
Drs. @Peddi and @Mitri: Would a score of, let&rsqu...

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
Can you comment a bit on the TC 4 vs TC 6 issue? T...

Medical Oncologist at Los Angeles VA Medical Center
Dr. @Susan M. Freeman, here is a previous discussi...

Please select the option that best describes you:

Does the magnitude of OncoType recurrence score above 26 inform decision between TC and AC/T in ER+ HER2- 1-3 node positive, postmenopausal patients with breast cancer?

Related Questions